Based on this evidence, our laboratory recently demonstrated that modulation of the ERα content can be used as a parameter to identify compounds that can alter ERα levels and prevent E2-dependent BC cell proliferation [3,13,14,15,20]. This evidence concerns the gene ESR1 and breast cancer.